RNS & Thalamic DBS
Intracranial neurostimulation for epilepsy has advanced significantly over the past two decades, with two distinct approaches now FDA-approved: responsive neurostimulation (RNS, NeuroPace) and deep brain stimulation (DBS) of the anterior nucleus of the thalamus. These devices represent complementary strategies—the RNS system uses a closed-loop paradigm to detect and disrupt seizure onset in real time, while thalamic DBS uses open-loop stimulation to modulate the seizure-generating network at a critical thalamocortical relay. Both therapies are palliative, offering meaningful seizure reduction in patients who are not candidates for resective surgery, with efficacy that continues to improve over years of treatment. The RNS system provides the unique diagnostic benefit of chronic ambulatory electrocorticography (ECoG), which can inform future treatment decisions including subsequent surgical interventions. Long-term data from pivotal trials and post-approval registries have established the safety and durability of both approaches, positioning intracranial neurostimulation as a cornerstone of treatment for complex drug-resistant epilepsy.
Bottom Line
- RNS (NeuroPace): Closed-loop intracranial device; detects seizure onset patterns on ECoG and delivers responsive stimulation; FDA-approved 2013 for drug-resistant focal epilepsy with ≤2 seizure foci
- RNS efficacy: Pivotal trial: 38% seizure reduction at 3 months (vs. 17% sham); long-term: 53% at 2 years, 66% at 6 years, 82% at 3 years in the post-approval study; seizure freedom for ≥6 months in 42% of patients (post-approval study)
- RNS diagnostic value: Chronic ambulatory ECoG provides objective seizure quantification; in bilateral MTLE, can identify a dominant focus for subsequent resection
- Anterior thalamic DBS: Open-loop bilateral stimulation of the anterior nucleus of thalamus (ANT); FDA-approved 2018 for drug-resistant focal epilepsy
- SANTE trial: Pivotal trial of ANT-DBS; 40% seizure reduction at 3 months (vs. 15% sham); 56% at 2 years; 69% at 5 years; 16% had ≥6-month seizure freedom in long-term follow-up
- DBS side effects: Depression (15%), memory symptoms (13%), paresthesias (18%); sleep disruption can be mitigated with programming
- Centromedian nucleus DBS: Emerging target for Lennox-Gastaut syndrome and generalized epilepsies; ESTEL trial showed promising results
Responsive Neurostimulation (RNS/NeuroPace)
Device and Mechanism
The RNS System is a cranially implanted, closed-loop neurostimulator that continuously monitors intracranial EEG (electrocorticography) from two leads, each with four contacts, placed in or on the putative epileptic foci. The device uses programmable detection algorithms to identify patient-specific seizure-onset patterns and delivers brief electrical stimulation to disrupt the seizure before it generalizes. The neurostimulator is housed in a ferrule (recessed into the skull), creating a cosmetically favorable profile.
Mechanisms of Action
- Acute seizure disruption: Brief electrical stimulation delivered at seizure onset disrupts the synchronization of epileptiform activity, terminating the seizure before clinical manifestation in many cases
- Long-term neuromodulation: Chronic stimulation appears to reduce seizure susceptibility over time through neuroplastic changes; this explains the progressive improvement in seizure reduction observed over years of therapy
- Detection individualization: Detection parameters are tuned to each patient's unique ECoG seizure-onset pattern using data uploaded at clinic visits; optimization improves with longer monitoring periods
Indications
The RNS System is FDA-approved for adults (≥18 years) with drug-resistant focal-onset seizures arising from one or two epileptogenic foci. It is particularly well-suited for:
- Bilateral seizure foci: Patients with bilateral mesial temporal lobe epilepsy where bilateral resection is not feasible
- Eloquent cortex seizure onset: When the seizure-onset zone overlaps with language, motor, or visual cortex, making resection unacceptable
- Prior failed resection: Persistent seizures after resective surgery with identifiable residual epileptogenic foci
- Diagnostic uncertainty: Bilateral or multifocal epilepsy where chronic ambulatory ECoG can clarify seizure lateralization and guide future interventions
Implantation
- Lead types: Depth electrodes (for hippocampal/deep targets) and cortical strip electrodes (for neocortical targets); each patient receives two leads (4 contacts each)
- Electrode placement: Based on presurgical evaluation data (Phase I and/or Phase II); targets the two most clinically relevant seizure foci
- Neurostimulator: Placed in a craniectomy-shaped ferrule in the skull; subcutaneous; connected to leads via tunneled wires
- Activation: Detection and stimulation programming begins approximately 1 month after implantation
Efficacy Data
| Study / Timepoint | Median Seizure Reduction | 50% Responder Rate | Seizure Freedom |
|---|---|---|---|
| Pivotal RCT — 3 months | 38% (treatment) vs. 17% (sham) | 29% (treatment) vs. 27% (sham) | — |
| Open-label — 1 year | 44% | ~50% | 9% (≥3 months) |
| Open-label — 2 years | 53% | ~55% | 9% (≥3 months) |
| Open-label — 6 years | 66% | ~66% | 28% (5–9-year follow-up, ≥3 months) |
| 9-year prospective study | ~75% | >70% | Continued improvement; cognition maintained or improved |
| Post-Approval Study (2025) — 3 years | 82% | — | 42% (≥6 months seizure-free) |
The Post-Approval Study (PAS) enrolled 324 patients from 32 centers—the largest prospectively enrolled FDA-reviewed trial in neuromodulation for drug-resistant focal epilepsy. The three-year data submitted to the FDA in November 2024 demonstrated an 82% median seizure reduction with 42% of patients experiencing at least 6 months of seizure freedom, substantially exceeding earlier pivotal trial results.
Chronic Ambulatory ECoG: The Diagnostic Bonus
The RNS system uniquely records continuous intracranial EEG data under naturalistic circumstances (while the patient takes their medications, sleeps, exercises, etc.), providing several diagnostic advantages:
- Objective seizure quantification: More accurate than patient diaries, which undercount seizures by 50% or more
- Seizure lateralization in bilateral MTLE: Long-term ECoG can reveal that a majority of seizures arise from one temporal lobe, identifying a subset of patients who can subsequently undergo curative mesial temporal resection
- Medication response monitoring: Objective measurement of seizure frequency changes with medication adjustments
- Circadian and multidien (multiday) seizure patterns: Long-term recording reveals seizure clustering patterns that inform treatment timing
RNS as a Diagnostic-Therapeutic Bridge
- In patients with bilateral mesial temporal lobe epilepsy, RNS recordings may identify that ≥90% of seizures arise from one hippocampus while on full medications
- This allows a staged approach: RNS implantation first (for both treatment and diagnosis), followed by palliative or curative mesial temporal resection guided by chronic ECoG data
- The RNS device can remain in place after resection to continue monitoring and treating contralateral seizures
- This paradigm transforms RNS from a purely palliative device into a diagnostic tool that may enable curative intervention
Complications and Safety
- Infection: 3% at 3 months; up to 12% in long-term follow-up; most managed with antibiotics; device explantation may be necessary in refractory cases
- Intracranial hemorrhage: ~3% at implantation; comparable to other stereotactic electrode procedures
- Stimulation-related side effects: Paresthesias, mood changes, memory symptoms—though formal neuropsychological testing shows no decline in memory or language function over 9 years of follow-up; in fact, statistically significant improvements in verbal memory and naming have been observed
- Device-related: Battery replacement every ~3–4 years (office procedure); lead revision for impedance issues; MRI compatibility is limited (specific protocols only)
Thalamic Deep Brain Stimulation
Anterior Nucleus of the Thalamus (ANT-DBS)
DBS targeting the anterior nucleus of the thalamus (ANT) was approved in Europe in 2010 and the United States in 2018 for treating drug-resistant focal epilepsy. The anterior nucleus is a critical relay in the circuit of Papez (hippocampus → fornix → mammillary bodies → anterior thalamus → cingulate cortex → hippocampus), making it an attractive target for modulating temporal lobe and limbic seizure networks.
Mechanism of Action
- Network desynchronization: Electrical stimulation of the ANT may disrupt the pathologic synchronization of thalamocortical circuits that facilitates seizure generation and propagation
- Seizure threshold modulation: Chronic stimulation may alter the excitability of cortical-subcortical networks, raising the seizure threshold over time
- Circuit of Papez modulation: Given the position of the ANT in the Papez circuit, stimulation may preferentially benefit temporal lobe epilepsy, though this has not been conclusively demonstrated in clinical trials
The SANTE Trial and Long-Term Data
| SANTE Trial Timepoint | Median Seizure Reduction | 50% Responder Rate | Seizure Freedom |
|---|---|---|---|
| 3-month blinded phase | 40% (treatment) vs. 15% (sham) | Significant improvement over sham | — |
| 1 year (open-label) | 41% | 43% | — |
| 2 years | 56% | 54% | — |
| 5 years | 69% | 68% | 16% (≥6 months seizure-free) |
| 10+ years | Stable or improved; 57 subjects with ≥10 years follow-up | Stable; favorable long-term safety | Durable improvement maintained |
The SANTE trial enrolled 110 adults with drug-resistant focal epilepsy across 17 US centers. Bilateral electrodes were implanted in the anterior nuclei of the thalamus, with half randomized to active stimulation and half to sham during the 3-month blinded phase. The trial demonstrated statistically significant seizure reduction with stimulation, and open-label extension data showed progressive improvement over 5–10 years of follow-up, with 938 cumulative device-years of experience.
The MORE Registry: Real-World Data
The European Medtronic Registry for Epilepsy (MORE) provides real-world comparative data for ANT-DBS. The registry enrolled 170 patients across 25 sites in 13 countries, with follow-up extending to 5 years:
- 2-year median seizure reduction: 33% (more modest than the SANTE trial, reflecting a real-world population)
- 5-year median seizure reduction: 56% (n = 46 with 5-year data)
- Seizure freedom at 2 years: 3% (lower than SANTE)
- 41% responder rate at last follow-up (n = 170)
- Most adverse events (76%) occurred in the first 2 years; no unanticipated device effects or symptomatic hemorrhages
Adverse Effects of ANT-DBS
| Side Effect | Incidence | Management |
|---|---|---|
| Infection | ~9% | Antibiotics; device explantation if refractory |
| Paresthesias | 18% | Usually transient; may resolve with parameter adjustment |
| Depressive symptoms | 15% | Monitor mood; consider programming changes (stimulation frequency/amplitude); antidepressant medication if needed; suicidality monitoring is recommended |
| Memory symptoms | 13% | Subjective complaints; formal neuropsychological testing may not show objective decline; proximity to fornix and mammillothalamic tract may contribute |
| Sleep disruption | Common | ANT stimulation can disrupt sleep architecture; can be mitigated by reducing stimulation intensity at night or using scheduled cycling that decreases during sleep hours |
| Intracranial hemorrhage | ~5% (implantation-related) | Most asymptomatic; rarely requires surgical evacuation |
Depression and Suicidality With Thalamic DBS
- Worsening depressive symptoms were reported in 15% of SANTE trial participants; this is significantly higher than the baseline rate and may be related to ANT stimulation effects on limbic circuitry
- One completed suicide occurred during the SANTE trial (relationship to stimulation uncertain)
- Patients should be screened for depression and suicidality before implantation and monitored regularly throughout treatment
- Programming adjustments (amplitude, frequency, cycling) may ameliorate mood side effects
- History of severe depression or active suicidal ideation is a relative contraindication that should be carefully weighed against potential benefits
Predictors of ANT-DBS Response
- Electrode position: Accuracy of electrode placement within the anterior nucleus may influence outcomes; medially placed electrodes engaging the mammillothalamic tract may have better results
- Temporal lobe epilepsy: May have better outcomes than extratemporal epilepsy, though this was not statistically significant in either the SANTE trial or the MORE registry
- MRI-positive epilepsy: May respond better than nonlesional epilepsy
- Stimulation parameters: Higher voltage and cycling duty cycles may be associated with greater seizure reduction; parameter optimization over time contributes to progressive improvement
Centromedian Nucleus DBS for Generalized Epilepsy
While the anterior nucleus is the FDA-approved target for focal epilepsy, the centromedian nucleus (CMN) of the thalamus has been proposed as a target for generalized and multifocal epilepsies, particularly Lennox-Gastaut syndrome (LGS). The centromedian nucleus is part of the intralaminar thalamic group with widespread cortical projections, making it a logical target for generalized seizure networks.
ESTEL Trial
The Electrical Stimulation of the Thalamus in Epilepsy of Lennox-Gastaut Syndrome (ESTEL) trial was a double-blind, randomized, sham-controlled trial of CMN-DBS in patients with LGS:
- Demonstrated significant reduction in tonic-clonic and tonic seizures with active stimulation compared with sham
- Improvements in electrographic seizure burden and quality of life measures
- Preliminary results are promising, but larger controlled trials are needed before regulatory approval
Selecting Between RNS and Thalamic DBS
- Choose RNS when: There are 1–2 identifiable seizure foci; the seizure-onset zone overlaps eloquent cortex; bilateral MTLE requires diagnostic clarification; the patient may benefit from chronic ECoG monitoring to guide future surgery
- Choose ANT-DBS when: Seizure-onset zones are broad or diffuse within the focal epilepsy network; temporal lobe epilepsy is the predominant seizure type; the patient has failed or is not a candidate for focal approaches (resection, LITT, RNS)
- Choose CMN-DBS (when available) when: Generalized epilepsy (particularly LGS) with tonic, atonic, or generalized tonic-clonic seizures not adequately controlled by VNS or corpus callosotomy
- Both RNS and DBS require specialized multidisciplinary centers with experience in device programming and follow-up
- Neither RNS nor DBS precludes future resective surgery if a more precise localization becomes possible
Comparison Table: VNS vs. RNS vs. DBS
| Feature | VNS | RNS (NeuroPace) | ANT-DBS |
|---|---|---|---|
| FDA approval | 1997 (US) | 2013 | 2018 (US) |
| Stimulation paradigm | Open-loop ± autostimulation | Closed-loop (responsive) | Open-loop (scheduled cycling) |
| Target | Left cervical vagus nerve | Seizure-onset zone(s); up to 2 foci | Bilateral anterior thalamic nuclei |
| Intracranial surgery | No | Yes (craniotomy + electrode implantation) | Yes (stereotactic electrode implantation) |
| Seizure reduction at 2 years | ~50% | ~53% | ~56% |
| Long-term seizure reduction | ~50% (stable) | 66% at 6 years; 82% at 3 years (PAS) | 69% at 5 years |
| Seizure freedom rates | 0–8% | 42% (≥6 months, PAS) | 16% (≥6 months, 5 years) |
| Diagnostic capability | None | Chronic ambulatory ECoG | Local field potentials (research use) |
| Key side effects | Hoarseness, cough; OSA aggravation | Infection (12% long-term); hemorrhage (3%) | Depression (15%); memory (13%); sleep disruption |
| Battery life | 3–11 years | ~3–4 years (office replacement) | 3–5 years (rechargeable models available) |
| MRI compatibility | Model-dependent; newer models MRI-conditional | Limited (specific protocols only) | MRI-conditional under specific SAR limits |
| Best for | Broad applicability; generalized epilepsy; LGS; first-line neuromodulation | 1–2 focal onsets; eloquent cortex; bilateral MTLE; diagnostic + therapeutic | Focal epilepsy with broad onset; temporal lobe epilepsy; possible future role in generalized epilepsy (CMN target) |
Practical Programming and Follow-Up
RNS Programming
RNS programming is an iterative process that evolves over months as more ECoG data accumulate:
- Detection optimization: Initial detection settings are based on the patient's known ictal onset pattern; detection sensitivity is adjusted at follow-up visits using stored ECoG data; both line-length and area detectors can be configured
- Stimulation parameters: Typical initial settings include current of 1–3 mA, frequency of 200 Hz, pulse width of 160 μs, and burst duration of 100 ms; parameters are adjusted based on detection accuracy and clinical response
- Data review: Patients upload ECoG data to the NeuroPace Patient Data Management System (PDMS) daily using a remote monitor; clinicians review stored ECoG events (detections, long episodes, scheduled recordings) at each visit
- Follow-up frequency: Monthly visits during the first 6 months for programming optimization; then every 3–6 months once detection and stimulation parameters are stable
- Battery replacement: The neurostimulator battery is replaced via a cranial procedure every 3–4 years; this is typically a same-day procedure under local or general anesthesia
DBS Programming
ANT-DBS programming follows a different paradigm from movement disorder DBS, as seizure improvement is gradual and effects are not immediately observable:
- Initial activation: Typically 1 month after implantation; standard starting parameters include voltage 2–5 V, frequency 145 Hz, pulse width 90 μs, with 1-minute ON and 5-minute OFF cycling
- Optimization: Gradual increase in voltage and adjustment of duty cycle over months; cycling parameters (ON/OFF times) are adjusted to balance efficacy with battery life and side effects
- Night-time programming: Scheduled reduced stimulation during sleep hours can mitigate DBS-related sleep disruption; this requires careful programming with time-based parameter changes
- Follow-up: Every 3–6 months for parameter checks; seizure diary review; battery status monitoring; rechargeable models (Percept PC) can record local field potentials for biomarker-guided programming
Neuromodulation Device Interactions and Precautions
- MRI safety: Both RNS and DBS have specific MRI-conditional protocols; always verify the device model and approved imaging conditions before ordering MRI; unauthorized MRI can cause tissue heating, device malfunction, or electrode displacement
- External defibrillation: Both devices should be interrogated after external defibrillation to check for reset or damage
- Electrocautery: Bipolar cautery is preferred during any surgery; monopolar cautery can conduct current through the device leads and damage tissue or the device; limit cautery to ≥15 cm from the device and leads
- End-of-life planning: If a patient with an implanted RNS or DBS device enters hospice or palliative care, device deactivation may be appropriate to reduce unnecessary interventions; this should be discussed proactively
- Pregnancy: Limited data on intracranial neurostimulation during pregnancy; the devices have not been systematically studied in pregnant women; generally continued at existing settings with close monitoring
Future Directions
- Adaptive DBS: Closed-loop DBS systems that detect seizure activity via local field potentials and adjust stimulation in real time are under investigation; this would bring the responsive paradigm of RNS to thalamic DBS
- Novel DBS targets: Hippocampal DBS, centromedian nucleus DBS for generalized epilepsy, and pulvinar stimulation are being explored in clinical trials
- RNS for pediatric populations: Ongoing studies evaluating RNS safety and efficacy in adolescents and children
- RNS for Lennox-Gastaut syndrome: NeuroPace completed enrollment in a feasibility study of RNS for LGS in December 2024
- Combination therapies: Sequential or concurrent use of multiple neuromodulation devices (e.g., VNS + RNS, VNS + DBS) is practiced at some centers, though systematic evidence is limited
- Biomarker-guided programming: Using chronic ECoG (RNS) or local field potential (DBS) biomarkers to optimize stimulation parameters and predict seizure recurrence
- Artificial intelligence: Machine learning algorithms applied to chronic ECoG or LFP data may improve seizure detection, predict breakthrough seizures, and automate parameter optimization
References
- Friedman D, Engel J. Surgical treatments, devices, and nonmedical management of epilepsy. Continuum (Minneap Minn) 2025;31(1):165–186.
- Morrell MJ; RNS System in Epilepsy Study Group. Responsive cortical stimulation for the treatment of medically intractable partial epilepsy. Neurology 2011;77(13):1295–1304.
- Heck CN, King-Stephens D, Massey AD, et al. Two-year seizure reduction in adults with medically intractable partial onset epilepsy treated with responsive neurostimulation: final results of the RNS System Pivotal trial. Epilepsia 2014;55(3):432–441.
- Bergey GK, Morrell MJ, Mizrahi EM, et al. Long-term treatment with responsive brain stimulation in adults with refractory partial seizures. Neurology 2015;84(8):810–817.
- Nair DR, Laxer KD, Weber PB, et al. Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy. Neurology 2020;95(9):e1244–e1256.
- NeuroPace. Data from the Long-Term Post-Approval Study of the RNS System in Focal Epilepsy. Presented at 2025 AAN Annual Meeting. April 2025.
- Fisher R, Salanova V, Witt T, et al. Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. Epilepsia 2010;51(5):899–908.
- Salanova V, Witt T, Worth R, et al. Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy. Neurology 2015;84(10):1017–1025.
- Salanova V, Sperling MR, Gross RE, et al. The SANTÉ study at 10 years of follow-up: effectiveness, safety, and sudden unexpected death in epilepsy. Epilepsia 2021;62(6):1306–1317.
- Peltola J, Colon AJ, Pimentel J, et al. Deep brain stimulation of the anterior nucleus of the thalamus in drug-resistant epilepsy in the MORE multicenter patient registry. Neurology 2023;100(18):e1852–e1865.
- Kaufmann E, Kienle T, Burdette D, et al. Long-term evaluation of anterior thalamic deep brain stimulation for epilepsy in the European MORE registry. Epilepsia 2024;65(7):1996–2010.
- Dalic LJ, Warren AEL, Bulluss KJ, et al. DBS of thalamic centromedian nucleus for Lennox-Gastaut syndrome (ESTEL trial). Ann Neurol 2022;91(2):253–267.
- Ryvlin P, Rheims S, Hirsch LJ, Sokolov A, Jehi L. Neuromodulation in epilepsy: state-of-the-art approved therapies. Lancet Neurol 2021;20(12):1038–1047.
- Hirsch LJ, Mirro EA, Salanova V, et al. Mesial temporal resection following long-term ambulatory intracranial EEG monitoring with a direct brain-responsive neurostimulation system. Epilepsia 2020;61(3):408–420.
- Fisher RS, Velasco AL. Electrical brain stimulation for epilepsy. Nat Rev Neurol 2014;10(5):261–270.